A comparative evaluation of a novel vaccine in APP/PS1 mouse models of alzheimer's disease

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Carrera, Iván ^a   Etcheverría, Ignacio ^a   Fernández Novoa, Lucía ^a   Lombardi, Valter Ruggero Maria ^a   Lakshmana, Madepalli Krishnappa ^b   Cacabelos, Ramón ^c   Vigo, Carmen ^d  

^a Department of Neuroscience EuroEspes Biotechnology Poligono de Bergondo Nave F ^*  (Spain)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^d Neuroscience Division Atlas Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; EB 101; FREUND ADJUVANT; IMMUNOLIPOSOME; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIBODY; LYSOPHOSPHOLIPID; OLIGOPEPTIDE; PEPTIDE FRAGMENT; PS1 ANTIGEN; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; VACCINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; IMMUNIZATION; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MOUSE; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; QUANTITATIVE ANALYSIS; ROTAROD TEST; SPLEEN CELL; TRANSGENIC MOUSE; ANALOGS AND DERIVATIVES; ANIMAL; ANTIBODY PRODUCTION; BRAIN; DISEASE MODEL; HUMAN; IMMUNOLOGY; PROCEDURES; VACCINATION;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION; LYSOPHOSPHOLIPIDS; MICE; MICE, TRANSGENIC; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; SPHINGOSINE; VACCINATION; VACCINES;

EID: 84924151448     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/807146     Document Type: Article

References (63)

1. R. Cacabelos, L. Fernandez-Novoa, V. Lombardi, Y. Kubota, and M. Takeda, "Molecular genetics of Alzheimer's disease and aging," Methods and Findings in Experimental and Clinical Pharmacology, vol. 27, pp. 1-573, 2005.
2. P. T. Nelson, I. Alafuzoff, E. H. Bigio et al., "Correlation of alzheimer disease neuropathologic changes with cognitive status: a review of the literature," Journal of Neuropathology and Experimental Neurology, vol. 71, no. 5, pp. 362-381, 2012.
3. J. Näslund, V. Haroutunian, R. Mohs et al., "Correlationbetween elevated levels of amyloid β-peptide in the brain and cognitive decline," Journal of the American Medical Association, vol. 283, no. 12, pp. 1571-1577, 2000.
4. A. Koyama, O. I. Okereke, T. Yang, D. Blacker, D. J. Selkoe, and F. Grodstein, "Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis," Archives of Neurology, vol. 69, no. 7, pp. 824-831, 2012.
5. A. M. Fagan, C. M. Roe, C. Xiong, M. A. Mintun, J. C. Morris, and D. M. Holtzman, "Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults," Archives of Neurology, vol. 64, no. 3, pp. 343-349, 2007.
6. S. Parvathy, P. Davies, V. Haroutunian et al., "Correlation between Aβ-40-, Aβ-42-, and Aβx-43-containing amyloid plaques and cognitive decline," Archives of Neurology, vol. 58, no. 12, pp. 2025-2032, 2001.
7. E. Karran, M. Mercken, and B. D. Strooper, "The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics," Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 698-712, 2011.
8. J. L. Jankowsky, D. J. Fadale, J. Anderson et al., "Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase," Human Molecular Genetics, vol. 13, no. 2, pp. 159-170, 2004.
9. L. Holcomb, M. N. Gordon, E. Mcgowan et al., "Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes," Nature Medicine, vol. 4, no. 1, pp. 97-100, 1998.
10. S. J. Webster, A. D. Bachstetter, and L. J. van Eldik, "Comprehensive behavioral characterization of an APP/PS-1 double knockin mouse model of Alzheimer's disease," Alzheimer's Research and Therapy, vol. 5, no. 3, article 28, 2013.
11. H. Xiong, D. Callaghan, J. Wodzinska et al., "Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer's disease," Neuroscience Bulletin, vol. 27, no. 4, pp. 221-232, 2011.
12. M. Garcia-Alloza, L. A. Borrelli, B. T. Hyman, and B. J. Bacskai, "Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice," Neurobiology of Aging, vol. 31, no. 12, pp. 2058-2068, 2010.
13. M. Meyer-Luehmann, M. Mielke, T. L. Spires-Jones et al., "A reporter of local dendritic translocation shows plaque-related loss of neural systemfunction in APP-transgenic mice," Journal of Neuroscience, vol. 29, no. 40, pp. 12636-12640, 2009.
14. E. Machová, V. Rudajev, H. Smyčková, H. Koivisto, H. Tanila, and V. Doležal, "Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice," Neurobiology of Disease, vol. 38, no. 1, pp. 27-35, 2010.
15. T. Malm, J. Koistinaho, and K. Kanninen, "Utilization of APPswe/PS1dE9 transgenic mice in research of Alzheimer's disease: focus on gene therapy and cell-based therapy applications," International Journal of Alzheimer's Disease, vol. 2011, Article ID 517160, 8 pages, 2011.
16. J. Lee and P. Han, "An update of animal models of alzheimer diseasewith a reevaluation of plaque depositions," Experimental Neurobiology, vol. 22, pp. 84-95, 2013.
17. D. Schenk, R. Barbour, W. Dunn et al., "Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse," Nature, vol. 400, no. 6740, pp. 173-177, 1999.
18. H. J. Fu, B. Liu, J. L. Frost, and C. A. Lemere, "Amyloid-β immunotherapy for Alzheimer's disease," CNS and Neurological Disorders-Drug Targets, vol. 9, no. 2, pp. 197-206, 2010.
19. 42 immunization," Neurology, vol. 61, no. 1, pp. 46-54, 2003.
20. J. A. R. Nicolll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller, "Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report," Nature Medicine, vol. 9, no. 4, pp. 448-452, 2003.
21. I. Ferrer, M. Boada Rovira, M. L. Sánchez Guerra, M. J. Rey, and F. Costa-Jussá, "Neuropathology and pathogenesis of encephalitis following amyloid-Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease immunization in Alzheimer's disease," Brain Pathology, vol. 14, no. 1, pp. 11-20, 2004.
22. D. H. Cribbs, A. Ghochikyan, V. Vasilevko et al., "Adjuvantdependent modulation of Th1 and Th2 responses to immunization with β-amyloid," International Immunology, vol. 15, no. 4, pp. 505-514, 2003.
23. 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial," The Lancet, vol. 372, no. 9634, pp. 216-223, 2008.
24. I. Carrera, I. Etcheverría, L. Fernández-Novoa, V. Lombardi, R. Cacabelos, and C. Vigo, "Vaccine development to treat Alzheimer's disease neuropathology in APP/PS1 transgenic mice," International Journal of Alzheimer's Disease, vol. 2012, Article ID 376138, 17 pages, 2012.
25. I. Carrera, I. Etcheverría, Y. Li et al., "Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-β vaccine," BioMed Research International, vol. 2013, Article ID 709145, 12 pages, 2013.
26. V. Anelli, R. Bassi, G. Tettamanti, P. Viani, and L. Riboni, "Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes," Journal of Neurochemistry, vol. 92, no. 5, pp. 1204-1215, 2005.
27. S. Schroeter, K. Khan, R. Barbour et al., "Immunotherapy reduces vascular amyloid-β in PDAPP mice," Journal of Neuroscience, vol. 28, no. 27, pp. 6787-6793, 2008.
28. Z. Suo, A. Cox, N. Bartelli et al., "GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment," Neurobiology of Aging, vol. 28, no. 12, pp. 1873-1888, 2007.
29. W. Kamphuis, C. Mamber, M. Moeton et al., "GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease," PLoS ONE, vol. 7, no. 8, Article ID e42823, 2012.
30. J. Lang, C. Vigo-Pelfrey, and F. Martin, "Liposomes composed of partially hydrogenated egg phosphatidylcholines: fatty acid composition, thermal phase behavior and oxidative stability," Chemistry and Physics of Lipids, vol. 53, no. 1, pp. 91-101, 1990.
31. D. Morgan, D. M. Diamond, P. E. Gottschall et al., "A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," Nature, vol. 408, no. 6815, pp. 982-985, 2000.
32. M. L. Brownlow, L. Benner, D. D'Agostino, M. N. Gordon, and D. Morgan, "Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology," PLoS ONE, vol. 8, no. 9, Article ID e75713, 2013.
33. M. Pride, P. Seubert, M. Grundman, M. Hagen, J. Eldridge, and R. S. Black, "Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis," Neurodegenerative Diseases, vol. 5, no. 3-4, pp. 194-196, 2008.
34. C. Wiessner, K.-H. Wiederhold, A. C. Tissot et al., "The secondgeneration active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects," The Journal of Neuroscience, vol. 31, no. 25, pp. 9323-9331, 2011.
35. D. Lambracht-Washington and R. Rosenberg, "Advances in the development of vaccines for Alzheimer's disease," Discovery Medicine, vol. 15, no. 84, pp. 319-326, 2013.
36. 1 receptor axis in themigration of neural stem cells toward a site of spinal cord injury," Stem Cells, vol. 25, no. 1, pp. 115-124, 2007.
37. S. S. Lee, C. H. Woo, J. D. Chang, and J. H. Kim, "Roles of Rac and cytosolic phospholipase A2 in the intracellular signalling in response to titanium particles," Cellular Signalling, vol. 15, no. 3, pp. 339-345, 2003.
38. E. Masliah, L. Hansen, A. Adame et al., "Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease," Neurology, vol. 64, no. 1, pp. 129-131, 2005.
39. A. Pilorget, B. Annabi, F. Bouzeghrane, J. Marvaldi, J. Luis, and R. Béliveau, "Inhibition of angiogenic properties of brain endothelial cells by platelet-derived sphingosine-1-phosphate," Journal of Cerebral Blood Flow and Metabolism, vol. 25, no. 9, pp. 1171-1182, 2005.
40. A. Wang, P. Das, R. C. Switzer III, T. E. Golde, and J. L. Jankowsky, "Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into themechanism of amyloid-β immunotherapy," Journal of Neuroscience, vol. 31, no. 11, pp. 4124-4136, 2011.
41. G. Krabbe, A. Halle, V. Matyash et al., "Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology," PLoS ONE, vol. 8, no. 4, Article ID e60921, 2013.
42. Y. H. Liu, B. Giunta, H.-D. Zhou, J. Tan, and Y. J. Wang, "Immunotherapy for Alzheimer disease-the challenge of adverse effects," Nature Reviews Neurology, vol. 8, no. 8, pp. 465-469, 2012.
43. B. Solomon, R. Koppel, D. Frankel, and E. Hanan-Aharon, "Disaggregation of Alzheimer β-amyloid by site-directed mAb," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 8, pp. 4109-4112, 1997.
44. F. Bard, C. Cannon, R. Barbour et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, vol. 6, no. 8, pp. 916-919, 2000.
45. R. B. DeMattos, K. R. Bales, D. J. Cummins, J. C. Dodart, S. M. Paul, and D. M. Holtzman, "Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8850-8855, 2001.
46. C. A. Lemere, E. T. Spooner, J. LaFrancois et al., "Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice," Neurobiology of Disease, vol. 14, no. 1, pp. 10-18, 2003.
47. 1-42," Journal of Neuroimmunology, vol. 132, no. 1-2, pp. 49-59, 2002.
48. R. Cacabelos, "Pharmacogenomics in Alzheimer's disease," Methods in Molecular Biology, vol. 448, pp. 213-357, 2008.
49. R. Cacabelos, "Pharmacogenomics and therapeutic strategies for dementia," Expert Review of Molecular Diagnostics, vol. 9, no. 6, pp. 567-611, 2009.
50. D. van Dam, R. D'Hooge, M. Staufenbiel, C. van Ginneken, F. van Meir, and P. P. de Deyn, "Age-dependent cognitive decline in the APP23 model precedes amyloid deposition," European Journal of Neuroscience, vol. 17, no. 2, pp. 388-396, 2003.
51. M. Dumont, C. Strazielle, M. Staufenbiel, and R. Lalonde, "Spatial learning and exploration of environmental stimuli in 24-month-old female APP23 transgenic mice with the Swedish mutation," Brain Research, vol. 1024, no. 1-2, pp. 113-121, 2004.
52. R. Lalonde, M. Dumont, M. Staufenbiel, C. Sturchler-Pierrat, and C. Strazielle, "Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation," Brain Research, vol. 956, no. 1, pp. 36-44, 2002.
53. F. J. Huff, F. Boller, F. Lucchelli, R. Querriera, J. Beyer, and S. Belle, "The neurologic examination in patients with probable Alzheimer's disease," Archives of Neurology, vol. 44, no. 9, pp. 929-932, 1987.
54. A. F. Pettersson, M. Engardt, and L. O. Wahlund, "Activity level and balance in subjects with mild Alzheimer's disease," Dementia and Geriatric Cognitive Disorders, vol. 13, no. 4, pp. 213-216, 2002.
55. L. Calandreau, B. Desgranges, R. Jaffard, and A. Desmedt, "Switching from contextual to tone fear conditioning and vice versa: the key role of the glutamatergic hippocampal-lateral septal neurotransmission," Learning & Memory, vol. 17, no. 9, pp. 440-443, 2010.
56. F. Trinchese, S. Liu, F. Battaglia, S. Walter, P. M. Mathews, and O. Arancio, "Progressive age-related development of Alzheimerlike pathology in APP/PS1 mice," Annals of Neurology, vol. 55, no. 6, pp. 801-814, 2004.
57. D. M. Wilcock, A. Rojiani, A. Rosenthal et al., "Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage," Journal of Neuroinflammation, vol. 1, article 24, 2004.
58. S. A. Ferguson, S. Sarkar, and L. C. Schmued, "Longitudinal behavioral changes in the APP/PS1 transgenic Alzheimer's Disease model," Behavioural Brain Research, vol. 242, no. 1, pp. 125-134, 2013.
59. D. Wilcock and C. Colton, "Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice," CNS and Neurological Disorders-Drug Targets, vol. 8, no. 1, pp. 50-64, 2009.
60. M. Grundman, S. Gilman, R. S. Black et al., "An alternative method for estimating efficacy of the AN1792 vaccine for alzheimer disease," Neurology, vol. 71, no. 9, pp. 697-698, 2008.
61. D. Boche, E. Zotova, R. O. Weller et al., "Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain," Brain, vol. 131, no. 12, pp. 3299-3310, 2008.
62. M. Pfeifer, S. Boncristiano, L. Bondolfi et al., "Cerebral hemorrhage after passive anti-aβ immunotherapy," Science, vol. 298, no. 5597, p. 1379, 2002.
63. M. M. Racke, L. I. Boone, D. L. Hepburn et al., "Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β," Journal of Neuroscience, vol. 25, no. 3, pp. 629-636, 2005.